drugset
drugset / Trial / NCT05148143

RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor

NCT05148143 ↗

Phase 2 Unknown 50 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.

Timeline

Start
2020-06-01
Primary completion
2022-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaplatin Unknown — —
Subject Raltitrexed Small molecule — —

Indications

bile duct adenoma